{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:09:23Z","timestamp":1793329763681,"version":"4.5.0"},"reference-count":116,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":1564,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1093\/annonc\/mdv221","type":"journal-article","created":{"date-parts":[[2015,5,4]],"date-time":"2015-05-04T20:32:47Z","timestamp":1430771567000},"page":"1533-1546","source":"Crossref","is-referenced-by-count":1530,"title":["Tailoring therapies\u2014improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015"],"prefix":"10.1016","volume":"26","author":[{"given":"A.S.","family":"Coates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.P.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Goldhirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.D.","family":"Gelber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gnant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Piccart-Gebhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Th\u00fcrlimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-J.","family":"Senn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Baselga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Bonnefoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"Burstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Castiglione-Gertsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S.","family":"Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Colleoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy E.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Di Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bent","family":"Ejlertsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Gelber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gnant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aron","family":"Goldhirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Harbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Huober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford A.","family":"Hudis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James N.","family":"Ingle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Jassem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zefei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Orecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kent Osborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann H.","family":"Partridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"de la Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine J.","family":"Piccart-Gebhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen I.","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiel J.T.","family":"Rutgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Sedlmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Semiglazov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ming","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat","family":"Th\u00fcrlimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Toi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Tutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunter","family":"von Minckwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Whelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdv221_bb0010","unstructured":"J Ferlay, ISoerjomataram, MErviket al. GLOBOCAN 2012 v 1.0, Cancer Incidence and Mortality Worldwide. 2013. Lyon, International Agency for Research on Cancer. IARC CancerBase No. 11."},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdv221_bb0015","first-page":"PG 0.1","article-title":"Evolution of the St. Gallen Consensus process for the optimal treatment of women with breast cancer","volume":"24","author":"Coates","year":"2015","journal-title":"Breast"},{"key":"10.1093\/annonc\/mdv221_bb0020","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1404037","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer","volume":"371","author":"Pagani","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv221_bb0025","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1412379","article-title":"Adjuvant ovarian suppression in premenopausal breast cancer","volume":"372","author":"Francis","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv221_bb0030","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1056\/NEJMoa1413204","article-title":"Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy","volume":"372","author":"Moore","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv221_bb0035","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1245\/s10434-013-3200-6","article-title":"Axillary dissection can be avoided in the majority of clinically node-negative patients undergoing breast-conserving therapy","volume":"21","author":"Dengel","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0040","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1200\/JCO.2013.53.3935","article-title":"Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer","volume":"32","author":"Moran","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0045","article-title":"NCIC-CTG MA.20: an intergroup trial of regional nodal irradiation in early breast cancer","volume":"29","author":"Whelan","year":"2011","journal-title":"J Clin Oncol Proceedings of the American Society of Clinical Oncology"},{"key":"10.1093\/annonc\/mdv221_bb0050","article-title":"Lymph node radiotherapy improves survival in breast cancer: 10 year results of the EORTC Radiation Oncology and Breast Cancer Groups phase III trial 22922\/10925","volume":"6","author":"Poortmans","year":"2013","journal-title":"ESTRO Congress Report"},{"key":"10.1093\/annonc\/mdv221_bb0055","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/annonc\/mdv159","article-title":"No clear effect of postoperative radiotherapy on survival of breast cancer patients with 1\u20133 positive nodes: a population-based study","volume":"26","author":"Nordenskjold","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0060","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa0906260","article-title":"Long-term results of hypofractionated radiation therapy for breast cancer","volume":"362","author":"Whelan","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv221_bb0065","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","article-title":"The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials","volume":"14","author":"Haviland","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0070","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"The Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdv221_bb0075","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"Sorlie","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdv221_bb0080","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1755-8794-5-44","article-title":"PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers","volume":"5","author":"Bastien","year":"2012","journal-title":"BMC Med Genomics"},{"key":"10.1093\/annonc\/mdv221_bb0085","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s12032-014-0163-9","article-title":"Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy","volume":"31","author":"Bayraktar","year":"2014","journal-title":"Med Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0090","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1200\/JCO.2012.46.1558","article-title":"Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy","volume":"31","author":"Dowsett","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0095","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/annonc\/mds512","article-title":"The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use","volume":"24","author":"Eiermann","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0100","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1200\/JCO.2012.43.4134","article-title":"Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer","volume":"31","author":"Prat","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0105","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1158\/1078-0432.CCR-10-1282","article-title":"A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer","volume":"16","author":"Nielsen","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv221_bb0110","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1186\/bcr3348","article-title":"Prognostic interaction between expression of p53 and estrogen receptor in patients with node-negative breast cancer: results from IBCSG Trials VIII and IX","volume":"14","author":"Coates","year":"2012","journal-title":"Breast Cancer Res"},{"key":"10.1093\/annonc\/mdv221_bb0115","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/annonc\/mdn037","article-title":"Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?","volume":"19","author":"Regan","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0120","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1186\/bcr2124","article-title":"Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures","volume":"10","author":"Wirapati","year":"2008","journal-title":"Breast Cancer Res"},{"key":"10.1093\/annonc\/mdv221_bb0125","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/sj.bjc.6603756","article-title":"Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients","volume":"96","author":"de Azambuja","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdv221_bb0130","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.breast.2013.11.007","article-title":"High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer","volume":"23","author":"Criscitiello","year":"2014","journal-title":"Breast"},{"key":"10.1093\/annonc\/mdv221_bb0135","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/annonc\/mdt564","article-title":"Reply to Ki67 in breast cancer: a useful prognostic marker!","volume":"25","author":"Denkert","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0140","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1093\/jnci\/djt306","article-title":"An international Ki67 reproducibility study","volume":"105","author":"Polley","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdv221_bb0145","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10549-013-2561-7","article-title":"Evolution of sites of recurrence after early breast cancer over the last 20 years: implications for patient care and future research","volume":"139","author":"Bouganim","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdv221_bb0150","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jso.23594","article-title":"Margins in breast conservation: a clinician's perspective and what the literature tells us","volume":"110","author":"Houssami","year":"2014","journal-title":"J Surg Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0155","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/jama.2011.90","article-title":"Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis","volume":"305","author":"Giuliano","year":"2011","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdv221_bb0160","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial","volume":"15","author":"Donker","year":"2014","journal-title":"Lancet Oncol"},{"issue":"5s suppl","key":"10.1093\/annonc\/mdv221_bb0165","article-title":"Recurrence score and quantitative ER expression to predict in late distant recurrence risk in ER+ BC after 5 years of tamoxifen","volume":"32","author":"Wolmark","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0170","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/1471-2407-14-177","article-title":"Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens","volume":"14","author":"Nielsen","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1093\/annonc\/mdv221_bb0175","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1200\/JCO.2014.55.6894","volume":"33","author":"Sestak","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0180","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/jnci\/djt244","article-title":"Factors predicting late recurrence for estrogen receptor-positive breast cancer","volume":"105","author":"Sestak","year":"2013","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1093\/annonc\/mdv221_bb0185","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1038\/bjc.2013.671","article-title":"The EndoPredict score provides prognostic information on late distant metastases in ER+\/HER2- breast cancer patients","volume":"109","author":"Dubsky","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdv221_bb0190","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1158\/1078-0432.CCR-13-0804","article-title":"Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence","volume":"19","author":"Zhang","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv221_bb0195","first-page":"269","article-title":"Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer","volume":"306","author":"Del Mastro","year":"2011","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdv221_bb0200","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1200\/JCO.2010.32.5704","article-title":"Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study","volume":"29","author":"Gerber","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0205","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JOP.2013.000957","article-title":"ASCO's approach to a learning health care system in oncology","volume":"9","author":"Sledge","year":"2013","journal-title":"J Oncol Pract"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdv221_bb0210","first-page":"PG 2.01","article-title":"Interpreting genomics data at a functional level: what are we learning from large molecular screening projects?","volume":"24","author":"Campbell","year":"2015","journal-title":"Breast"},{"key":"10.1093\/annonc\/mdv221_bb0215","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/annonc\/mdu026","article-title":"High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041\/BIG 03-04 MINDACT trial","volume":"25","author":"Viale","year":"2014","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdv221_bb0220","first-page":"PG 2.03","article-title":"Discrepancies between genetic tools and immunohistochemistry: bad pathology and good signature, and vice-versa","volume":"24","author":"Reis-Filho","year":"2015","journal-title":"Breast"},{"key":"10.1093\/annonc\/mdv221_bb0225","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1186\/bcr3679","article-title":"Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes","volume":"16","author":"Maisonneuve","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdv221_bb0230","first-page":"PG 2.04","article-title":"A bad tumor biomarker is as bad as a bad drug: the gap between genomics data and phenotype to predict response","volume":"24","author":"Viale","year":"2015","journal-title":"Breast"},{"key":"10.1093\/annonc\/mdv221_bb0235","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1158\/1078-0432.CCR-13-0239","article-title":"Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study","volume":"20","author":"Prat","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv221_bb0240","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0245","doi-asserted-by":"crossref","first-page":"R73","DOI":"10.1186\/bcr3690","article-title":"Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study","volume":"16","author":"Schneeweiss","year":"2014","journal-title":"Breast Cancer Res"},{"key":"10.1093\/annonc\/mdv221_bb0250","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1634\/theoncologist.2012-0397","article-title":"Molecular characterization of basal-like and non-basal-like triple-negative breast cancer","volume":"18","author":"Prat","year":"2013","journal-title":"Oncologist"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdv221_bb0255","first-page":"PG 8.01","article-title":"Primary systemic therapy for clinicians: medical and research perspectives","volume":"24","author":"Loibl","year":"2015","journal-title":"Breast"},{"key":"10.1093\/annonc\/mdv221_bb0260","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1158\/1078-0432.CCR-13-0799","article-title":"Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes","volume":"19","author":"Masuda","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv221_bb0265","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1093\/annonc\/mdv221_bb0270","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1200\/JCO.2013.55.0491","article-title":"Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199","volume":"32","author":"Adams","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0275","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1093\/annonc\/mdu112","article-title":"Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial","volume":"25","author":"Loi","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0280","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS14-S1-06","article-title":"Stromal tumor-infiltrating lymphocytes (S-TILs): in the alliance N9831 trial S-TILs are associated with chemotherapy benefit but not associated with trastuzumab benefit","volume":"75","author":"Perez","year":"2015","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdv221_bb0285","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-14-1801","article-title":"Adaptive upregulation of EGFR limits attenuation of tumor growth by neutralizing IL6 antibodies, with implications for combined therapy in ovarian cancer","author":"Milagre","year":"2015","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdv221_bb0290","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdv221_bb0295","first-page":"PG 4.02","article-title":"Immune pathways and immunome as a target","volume":"24","author":"Curigliano","year":"2015","journal-title":"Breast"},{"issue":"Suppl","key":"10.1093\/annonc\/mdv221_bb0300","doi-asserted-by":"crossref","first-page":"S1-09","DOI":"10.1158\/1538-7445.SABCS14-S1-09","article-title":"A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer","author":"Nanda","year":"2015","journal-title":"Cancer Res Suppl"},{"key":"10.1093\/annonc\/mdv221_bb0305","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0310","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2014.57.0085","article-title":"Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1\/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105","author":"Telli","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5s","key":"10.1093\/annonc\/mdv221_bb0315","article-title":"Pathological complete response (pCR) rates after carboplatin-containing neoadjuvant chemotherapy in patients with germline BRCA (gBRCA) mutation and triple-negative breast cancer (TNBC): results from GeparSixto","volume":"32","author":"von Minckwitz","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0320","doi-asserted-by":"crossref","first-page":"S3-01","DOI":"10.1158\/1538-7445.SABCS14-S3-01","article-title":"TNT: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1\/2 breast cancer CRUK\/07\/012)","volume":"75","author":"Tutt","year":"2014","journal-title":"Cancer Res Suppl"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdv221_bb0325","first-page":"PG 5.03","article-title":"Targeting PIK3CA pathway","volume":"24","author":"Baselga","year":"2015","journal-title":"Breast"},{"key":"10.1093\/annonc\/mdv221_bb0330","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1158\/1078-0432.CCR-13-0190","article-title":"Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer","volume":"19","author":"Andre","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv221_bb0335","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1093\/annonc\/mdu390","article-title":"Phase I\/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors","volume":"25","author":"Soria","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0340","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1200\/JCO.2012.47.8313","article-title":"Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"31","author":"Phillips","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0345","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1056\/NEJMsr1407164","article-title":"Atypical hyperplasia of the breast\u2014risk assessment and management options","volume":"372","author":"Hartmann","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv221_bb0350","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1093\/annonc\/mdu053","article-title":"Which threshold for ER positivity? A retrospective study based on 9639 patients","volume":"25","author":"Yi","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0355","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/cr.2014.71","article-title":"An epigenomic approach to therapy for tamoxifen-resistant breast cancer","volume":"24","author":"Feng","year":"2014","journal-title":"Cell Res"},{"key":"10.1093\/annonc\/mdv221_bb0360","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1093\/annonc\/mdt350","article-title":"Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial","volume":"24","author":"Denkert","year":"2013","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdv221_bb0365","first-page":"PG 7.04","article-title":"Developing Ki67 as a useful marker","volume":"24","author":"Denkert","year":"2015","journal-title":"Breast"},{"key":"10.1093\/annonc\/mdv221_bb0370","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/modpathol.2015.38","article-title":"An international study to increase concordance in Ki67 scoring","volume":"28","author":"Polley","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1093\/annonc\/mdv221_bb0375","article-title":"Standardized Ki67 diagnostics using automated scoring\u2014clinical validation in the GeparTrio Breast Cancer study","author":"Klauschen","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv221_bb0380","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","volume":"33","author":"Sikov","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0385","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","article-title":"Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial","volume":"15","author":"von Minckwitz","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0390","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1200\/JCO.2014.58.1967","article-title":"Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers","volume":"33","author":"Denkert","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0395","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2014.55.7876","article-title":"PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (HER2) therapy in primary HER2-overexpressing breast cancer","author":"Loibl","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0400","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2014.55.2158","article-title":"PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer","author":"Majewski","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0405","doi-asserted-by":"crossref","unstructured":"V Guarneri, MDieci, LCarbogninet al. Activity of neoadjuvant lapatinib plus trastuzumab for early breast cancer according to PIK3CA mutations: pathological complete response (pCR) rate in the CherLOB study and pooled analysis of randomized trials. Ann Oncol 2014; 25(Suppl 4): iv85\u2013iv109.","DOI":"10.1093\/annonc\/mdu327.2"},{"key":"10.1093\/annonc\/mdv221_bb0410","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/bjc.2013.151","article-title":"Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and\/or progesterone receptor-positive breast cancer","volume":"108","author":"Allevi","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdv221_bb0415","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/jnci\/djk020","article-title":"Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer","volume":"99","author":"Dowsett","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdv221_bb0420","first-page":"PG 8.02","article-title":"Neoadjuvant endocrine therapy: patient selection, treatment duration and surrogate endpoints","volume":"24","author":"Dowsett","year":"2015","journal-title":"Breast"},{"key":"10.1093\/annonc\/mdv221_bb0425","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S1470-2045(14)70320-1","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response","volume":"15","author":"de Azambuja","year":"2014","journal-title":"Lancet Oncol"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdv221_bb0430","first-page":"LBA 4","volume":"32","author":"Piccart-Gebhart","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0435","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1158\/1078-0432.CCR-14-1760","article-title":"The neoadjuvant model is still the future for drug development in breast cancer","volume":"21","author":"DeMichele","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdv221_bb0440","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10549-013-2745-1","article-title":"Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998\u20132002","volume":"142","author":"Yao","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdv221_bb0445","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s10549-011-1479-1","article-title":"The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer","volume":"128","author":"Narod","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdv221_bb0450","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1001\/jama.2014.10707","article-title":"Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998\u20132011","volume":"312","author":"Kurian","year":"2014","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdv221_bb0455","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ejso.2011.12.014","article-title":"Increasing rates of contralateral prophylactic mastectomy\u2014a trend made in USA?","volume":"38","author":"Guth","year":"2012","journal-title":"Eur J Surg Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0460","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO.2012.44.1956","article-title":"Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial","volume":"31","author":"Partridge","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0465","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","article-title":"Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study","volume":"14","author":"Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0470","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","article-title":"Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC Study","volume":"33","author":"Boileau","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0475","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/SLA.0000000000000551","article-title":"Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance)","volume":"261","author":"Boughey","year":"2015","journal-title":"Ann Surg"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdv221_bb0480","first-page":"PG 9.02","article-title":"Feasibility of sentinel node biopsy in breast cancer after neoadjuvant treatment","volume":"24","author":"Galimberti","year":"2015","journal-title":"Breast"},{"key":"10.1093\/annonc\/mdv221_bb0485","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1245\/s10434-014-4122-7","article-title":"Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapy","volume":"22","author":"Ataseven","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdv221_bb0490","first-page":"PG 10.01","article-title":"Hypofractionated radiotherapy in early breast cancer: clinical, dosimetric and radio-genomic issues","volume":"24","author":"Yarnold","year":"2015","journal-title":"Breast"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdv221_bb0495","first-page":"PG 10.02","article-title":"Evolving standards in breast cancer radiotherapy: who should receive locoregional RT?","volume":"24","author":"Whelan","year":"2015","journal-title":"Breast"},{"key":"10.1093\/annonc\/mdv221_bb0500","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.3109\/0284186X.2014.925579","article-title":"CT-planned internal mammary node radiotherapy in the DBCG-IMN study: benefit versus potentially harmful effects","volume":"53","author":"Thorsen","year":"2014","journal-title":"Acta Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0505","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mdu544","article-title":"Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12","volume":"26","author":"Gnant","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0510","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2014.55.6993","article-title":"Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group","volume":"32","author":"Tevaarwerk","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0515","first-page":"S3-09","author":"Ribi","year":"2014","journal-title":"Cancer Res Suppl"},{"issue":"Suppl 15","key":"10.1093\/annonc\/mdv221_bb0520","first-page":"#557","volume":"32","author":"Bernhard","year":"2015","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdv221_bb0525","first-page":"PG 11.03","article-title":"Predicting benefit of endocrine therapy","volume":"24","author":"Regan","year":"2015","journal-title":"Breast"},{"key":"10.1093\/annonc\/mdv221_bb0530","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1093\/annonc\/mdq738","article-title":"Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1\u201398 randomized trial","volume":"22","author":"Viale","year":"2011","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdv221_bb0535","first-page":"PG 6.03","article-title":"Obesity and insulin resistance: clinical relevance and research priorities","volume":"24","author":"Goodwin","year":"2015","journal-title":"Breast"},{"key":"10.1093\/annonc\/mdv221_bb0540","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1200\/JCO.2011.40.6405","article-title":"Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101","volume":"30","author":"Shulman","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0545","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1200\/JCO.2013.54.6119","article-title":"Risk of marrow neoplasms after adjuvant breast cancer therapy: The National Comprehensive Cancer Network Experience","volume":"33","author":"Wolff","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0550","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ejca.2014.11.024","article-title":"Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors","volume":"51","author":"Eckhoff","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdv221_bb0555","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.2013.53.9288","article-title":"Trastuzumab-associated cardiac events at 8 years of median follow-up in the herceptin adjuvant trial (BIG 1-01)","volume":"32","author":"de Azambuja","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv221_bb0560","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1406281","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer","volume":"372","author":"Tolaney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv221_bb0565","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.breast.2015.01.005","article-title":"Pregnancy after breast cancer: are young patients willing to participate in clinical studies?","volume":"24","author":"Pagani","year":"2015","journal-title":"Breast"},{"key":"10.1093\/annonc\/mdv221_bb0570","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","article-title":"Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome in 100,000 randomised women in 123 randomised trials","volume":"379","author":"Early Breast Cancer Trialists' Collaborative Group","year":"2012","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdv221_bb0575","first-page":"PG 12.02","article-title":"Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes","volume":"24","author":"Hart","year":"2015","journal-title":"Breast"},{"key":"10.1093\/annonc\/mdv221_bb0580","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv221_bb0585","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419318502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419318502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/26\/8\/1533\/16699826\/mdv221.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T21:56:19Z","timestamp":1691618179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419318502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":116,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0923753419318502"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdv221","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}